FDA's emergency nod for convalescent plasma sparks questions of whether it's bowing to Trump Trump pushes for preelection fast-tracked approval of AstraZeneca COVID-19 vaccine: report Meet a J&J scientist on the front lines of stopping a global pandemic Can Gilead's remdesivir reach moderate COVID-19 patients after mixed data? Moderna on the verge of European supply deal for 160M doses of COVID-19 vaccine Majority of nursing homes say they won't last another year under current financial conditions: survey Moody's: Insurers' EBITDA up 87% year over year in Q2 Florida hospitals lost nearly $4B through end of June due to COVID-19: industry report AstraZeneca ropes in Catalent gene therapy site to produce viral vectors for COVID-19 vaccine FiercePharmaPolitics—Is the 'deep state' running the FDA? Trump tweet sparks pushback amid COVID-19 fight Aslan hopes to roar again as Dupixent rival test resumes after COVID-19 chaos Featured Story | By Eric Sagonowsky Hospitalized COVID-19 patients in the U.S. have another treatment option in the U.S. after the FDA’s emergency authorization for convalescent plasma on Sunday. But the decision prompted pushback from experts who questioned the data and wondered whether the FDA is acting under pressure from President Donald Trump. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor President Donald Trump is considering fast-tracking the authorization of AstraZeneca’s COVID-19 vaccine to ensure a jab is available in time for the November election, according to the Financial Times. The mooted plan is to allow AstraZeneca to gain emergency use authorization on the basis of a 10,000-subject U.K. clinical trial. read more By Heather Landi As drug giant Johnson & Johnson gears up for the industry's largest COVID-19 vaccine trial to date, Fierce Healthcare spoke with one of the company's top scientists about the hunt for a vaccine. Find out how Hanneke Schuitemaker's team has been able to work at an accelerated pace and the one thing she wants the public to know. read more By Angus Liu In the landmark ACTT-1 clinical trial run by the National Institutes of Health, the benefit of Gilead Sciences’ remdesivir wasn't obvious in moderate COVID-19 cases. In a new clinical trial, the antiviral once again showed mixed results in moderately ill patients, raising questions as to whether it’s up for a full FDA nod covering that population. read more By Kyle Blankenship Moderna faces a slew of challenges in keeping with its bigger competitors in the chase for a COVID-19 vaccine, most crucially its limited manufacturing and distribution capacity. With its supply chain on the upswing, Moderna is looking to nab an expansive distribution deal with the EU as a complement to its multibillion-dollar U.S. pact. read more By Tina Reed A majority of long-term care providers indicated they won't last another year under current financial conditions caused by the COVID-19 pandemic, recent surveys found. read more By Paige Minemyer Insurers posted "unusually strong" financial performance in the second quarter, according to a new analysis from Moody's Investors Service. read more By Robert King A hospital industry report pegs losses for Florida hospitals from COVID-19 at nearly $4 billion through the end of June, as federal relief funds failed to fill the gap. read more By Kyle Blankenship In the hunt for a novel coronavirus vaccine, British drugmaker AstraZeneca has raced to the front of the pack with promising interim data and a slew of proposed supply deals. One of its earliest partners in the effort, New Jersey CDMO Catalent, is now adding to its responsibilities as the vaccine nears regulatory scrutiny. read more By Eric Sagonowsky It’s been a contentious week at the FDA after attacks from President Donald Trump and his allies, who've claimed “deep state” employees within the agency are undercutting the fight against the COVID-19 pandemic. The accusation met with quick pushback from former agency officials and lawmakers alike. read more By Ben Adams Singapore-based Aslan Pharmaceuticals is hitting go again on its stalled dermatitis study. read more | 